

*The Annual Meeting of the Nutrition Society and the British Association for Parenteral and Enteral Nutrition was held at Harrogate International Centre, Harrogate on 27–28 November 2007*

## Nutrition Society and BAPEN Medical Symposium on ‘Nutrition support in cancer therapy’

### An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer

Donald C. McMillan

*University Dept of Surgery, Royal Infirmary, Glasgow G31 2ER, UK*

Progressive involuntary weight loss, in particular the loss of lean tissue, is common in patients with advanced cancer and has long been recognised to result in a deterioration in performance status and quality of life, increased morbidity and mortality. The aetiology of such weight loss or cachexia is complex and involves both tumour and host responses. Thus, identification of patients who are or are likely to become cachectic has been problematic. In addition to a reduction in appetite and increased satiety leading to poor dietary intake, there is now increasing clinical evidence that the activation of a chronic ongoing systemic inflammatory response is one of the earliest and most important contributory factors to cachexia. Such findings help to explain the failure of simple nutritional programmes to reverse weight loss adequately in patients with cancer. In the present paper the development of an inflammation-based score is described, which is derived from the acute-phase proteins C-reactive protein and albumin and is termed the Glasgow prognostic score (GPS). Its value as a predictor of survival, independent of tumour stage, performance status and treatment (active or palliative), has been shown in a variety of advanced common solid tumours. The nature of the relationship between the GPS, appetite, body composition, performance status and quality of life of the patient with advanced cancer will be described. Recently, it has become evident that the systemic inflammatory response is also present in a smaller proportion of patients with primary operable cancer and is also predictive of disease progression and poor survival. The role of GPS in clinical decision making will be discussed.

#### Cancer: Nutrition: Prognosis: Inflammation-based score

Cancer is the leading cause of death worldwide among individuals aged 35–64 years and globally is responsible for  $>0.5 \times 10^6$  deaths annually. In the UK approximately one in three contract the disease in their life time and one in four of the population die from cancer<sup>(1)</sup>.

Although much research is devoted to finding a cure for cancer, for the majority of patients with cancer the disease will progress either locally or become metastatic. Thus, anticipated survival is a major factor to be taken into consideration when deciding whether active intervention or palliation is appropriate.

Establishing the tumour stage of the patient has assumed paramount importance in the treatment of cancer.

However, it is becoming increasingly recognised that the information that tumour stage provides on disease progression is inadequate. In particular, it is well recognised that predicting life expectancy of patients with advanced cancer is difficult and clinicians often overestimate survival<sup>(2,3)</sup>. Current methods of assessing the suitability of such patients for treatment are usually based on host factors such as weight loss or performance status, since cancer patients who lose weight and have reduced performance status have a poorer prognosis than those who remain weight stable independent of tumour stage and anticancer therapies such as chemotherapy or radiotherapy treatment<sup>(4–6)</sup>.

**Abbreviation:** GPS, Glasgow prognostic score.

**Corresponding author:** Dr Donald C. McMillan, fax +44 141 552 3229, email d.c.mcmillan@clinmed.gla.ac.uk

The clear link between weight loss, poor performance status and poor prognosis<sup>(7-9)</sup> is probably a result of the preferential loss of skeletal muscle<sup>(10-12)</sup>. It has been suggested that the loss of adipose tissue accounts for the majority of the weight loss, but the loss of muscle accounts for most of the morbidity and mortality<sup>(13,14)</sup>.

However, the extent of weight loss that is prognostic is not well defined<sup>(15,16)</sup> and performance status is recognised to be subjective<sup>(17)</sup> and therefore their reliability has been questioned.

### Aetiology of weight loss and reduced performance status

It is of interest that although the majority of patients with advanced cancer lose weight and have a poorer performance status, the extent varies according to tumour type. Patients with lung and gastrointestinal cancers tend to lose considerable amounts of weight and have reduced performance status early on in their illness.

Given that weight loss and reduced performance status are such an important problem in patients with cancer in terms of morbidity and mortality, the reversal of this process would seem to be a priority. However, the definitive method of treating these symptoms, i.e. removal of the tumour, is not an option in the majority of patients.

Weight loss results from an energy imbalance between energy intake and energy expenditure. This negative energy balance may, thus, be related to a reduced food intake, increased energy expenditure or a combination of both.

There have been many studies that have investigated the energy expenditure in patients with lung and gastrointestinal cancers<sup>(18-21)</sup>. Most studies have found an increased energy expenditure in patients with cancer who are losing weight, in contrast with the body's normal response to starvation that produces a reduced metabolic rate.


It has been reported that an elevated resting energy expenditure in patients with pancreatic cancer is associated with the presence of a systemic inflammatory response, as evidenced by an elevated C-reactive protein concentration<sup>(21)</sup>. Similar results have been reported in other tumour types associated with weight loss, including lung cancer<sup>(22,23)</sup>.

It is therefore of interest that the presence of a systemic inflammatory response has also been shown to be associated with a reduction in the body cell mass (lean tissue) as measured by total body K<sup>(12,24)</sup>.

Further evidence of the central importance of the systemic inflammatory response is that the use of anti-inflammatory agents is associated with moderation of weight loss and the maintenance of performance status and quality of life in patients with advanced cancer<sup>(25-27)</sup>.

### Development of a systemic-inflammation-based score

There are a myriad of systemic responses to inflammation in human subjects resulting from infection, tissue injury, immunological disorders or cancer. These responses



**Fig. 1.** Relationship between C-reactive protein and albumin in a variety of common solid tumours. (····), Colo-rectal cancer; (—), gastric cancer or breast cancer; (---), bronchogenic cancer. (From McMillan *et al.*<sup>(30)</sup>.)

involve alterations in neuroendocrine metabolism (including the endocrine hormones), haematopoietic changes (including the IL, interferons and the haematopoietic growth factors), changes in protein and energy metabolism (including loss of muscle protein) and acute-phase proteins<sup>(28)</sup>. The liver is central to the elaboration of the systemic inflammatory response. Hepatocytes are stimulated to synthesise and release into the systemic circulation a variety of acute-phase proteins, such as C-reactive protein, which initiate or sustain the systemic inflammatory response.

The systemic inflammatory response, manifested by elevation of C-reactive protein, may simply reflect a non-specific inflammatory response secondary to tumour hypoxia and necrosis or local tissue damage because apoptosis is a relatively 'clean' form of cell death in that it does not elicit an inflammatory immune response. These features are distinct from cells undergoing necrosis as a result of acute cell damage or 'accidental' cell death<sup>(29)</sup>.

In patients with cancer there is evidence of the stereotypical acute-phase protein response of C-reactive protein increasing and albumin falling, and this relationship is similar across different tumour types<sup>(30)</sup> (Fig. 1). C-reactive protein, because of its sensitivity, specificity and reproducibility of analysis in hospital laboratories, is most commonly used to assess the magnitude (whether acute or chronic) of the systemic inflammatory response<sup>(28,31)</sup>. Indeed, the magnitude of the increase in C-reactive protein concentrations has been shown to be associated with poorer survival in patients with cancer, particularly in patients with advanced disease<sup>(32-35)</sup>.

It has been shown that in patients diagnosed with inoperable non-small-cell lung cancer and followed to death ( $n$  106) there is, with increasing C-reactive protein concentrations from normal ( $<10$  mg/l) to elevated (11–100 mg/l) and to highly-elevated ( $>100$  mg/l), an increasing proportion of patients with  $>5\%$  weight loss, poorer performance status and more fatigue<sup>(36)</sup>. Also, the more elevated the C-reactive protein concentration the

**Table 1.** Cumulative prognostic scores and survival in patients with inoperable non-small-cell lung cancer (*n* 161); univariate survival analysis (from Forrest *et al.*<sup>(38)</sup>)

Combinations compared	<i>n</i>	Cumulative scores	Survival (months)		HR	95% CI	<i>P</i>		
			Median	95% CI					
CRP and stage	14	CRP (mg/l)	Stage	0	18.2	14.5, 21.9	1.73	1.23, 2.33	<0.001
				1	10.4	7.9, 12.8			
	>10	III	1	8.9	5.5, 12.3				
		IV	2	6.1	3.4, 8.7				
CRP and ECOG*	23	CRP (mg/l)	ECOG*	0	17.9	15.5, 20.3	1.79	1.37, 2.35	<0.001
				1					
	>10	0-1	1	9.0	4.3, 13.6				
		2-4	2	4.2	2.2, 6.2				
CRP and albumin	27	CRP (mg/l)	Albumin (g/l)	0	17.0	11.4, 22.6	2.00	1.47, 2.70	<0.001
				1					
	>10	≥35	1	8.9	6.3, 11.4				
		<35	2	3.9	0.8, 7.1				
Stage and ECOG*	40	Stage	ECOG*	0	16.1	9.5, 22.6	1.73	1.33, 2.24	<0.001
				1					
	IV	0-1	1	10.4	5.8, 14.9				
		2-4	2	3.6	1.7, 5.6				

CRP, C-reactive protein; HR, hazard ratio.

\*Eastern Cooperative Oncology Group performance status, which assesses the well-being of patients with cancer and their ability to perform ordinary tasks<sup>(37)</sup>.

lower the albumin concentrations and the poorer the cancer-specific survival, independent of tumour stage.

In order to examine how the prognostic value of an elevated C-reactive protein concentration (>10 mg/l) might be used clinically, the prognostic value of the combinations of C-reactive protein and stage, C-reactive protein and performance status (Eastern Cooperative Oncology Group performance status, which assesses the well-being of patients with cancer and their ability to perform ordinary tasks<sup>(37)</sup>), C-reactive protein and albumin (<35 g/l) together with stage and performance status were compared in 161 patients with inoperable non-small-cell lung cancer<sup>(38)</sup> (Table 1). On multivariate analysis, when the three scores based on the combinations of the systemic inflammatory response and stage, performance status and albumin were compared with the combination of stage and performance status, only the score based on the combination of the systemic inflammatory response and albumin (HR 1.70 (95% CI 1.23, 2.35); *P*<0.001) and the score based on stage and performance status (HR 1.48 (95% CI 1.12, 1.95); *P*=0.006) were found to retain independent significance.

The combination of C-reactive protein and albumin into a score (0, 1, 2) has much to commend it, since it has independent prognostic value, is simple to measure, routinely available and well standardised. This score now termed the Glasgow prognostic score (GPS) has been defined as follows: patients with both an elevated C-reactive protein (>10 mg/l) and hypoalbuminaemia (<35 g/l) are allocated a score of 2; patients in whom only one of these biochemical abnormalities is present are allocated a score of 1; patients in whom neither of these

abnormalities is present are allocated a score of 0. However, in the clinical study the score of 1 was most commonly found to be a result of an elevated C-reactive protein (thirty-three of thirty-five patients), emphasising the inflammatory basis of the GPS<sup>(38)</sup>.

#### Application of a systemic-inflammation-based score in patients with advanced cancer

The prognostic value of the GPS was then evaluated further in a variety of advanced cancers including non-small-cell lung<sup>(39)</sup>, breast<sup>(40)</sup>, gastro-oesophageal<sup>(41,42)</sup>, pancreatic<sup>(43)</sup>, renal<sup>(44)</sup> and colo-rectal<sup>(45)</sup> cancers. These studies (Table 2) have demonstrated that the prognostic value of the GPS is independent of tumour stage (all studies) and conventional scoring systems<sup>(44)</sup>, superior to performance status<sup>(39,42)</sup> and superior to other markers of the systemic inflammatory response such as leucocyte or lymphocyte counts<sup>(39,40,42,44,45)</sup>.

Having established a scoring system (the GPS) based on the systemic inflammation-driven loss of weight, lean tissue and performance status, it was of interest to examine its relationship with the general biochemical disturbance of patients with advanced cancer<sup>(46)</sup>. The GPS was found to be normal in all the controls (*n* 13), but abnormal in 78% of the group with lung and gastrointestinal cancer (*n* 50). In addition to lower BMI and poorer performance status, serum concentrations of Na, chloride, creatine kinase, Zn and vitamin D were found to be lower in the group with cancer, whereas concentrations of Ca, Cu, alkaline phosphatase and  $\gamma$ -glutamyl transferase were raised. In the

**Table 2.** Systemic inflammatory response, as evidenced by the Glasgow prognostic score (GPS), as a prognostic factor in advanced inoperable cancer

Study	Tumour type	<i>n</i>	Comments
Forrest <i>et al.</i> <sup>(39)</sup>	Lung	109	GPS superior to ECOG*
Al Murri <i>et al.</i> <sup>(40)</sup>	Breast	96	GPS independent of stage and treatment
Crumley <i>et al.</i> <sup>(41)</sup>	Gastro-oesophageal	258	GPS independent of stage and treatment
Glen <i>et al.</i> <sup>(43)</sup>	Pancreatic	187	GPS independent of stage
Ramsey <i>et al.</i> <sup>(44)</sup>	Renal	119	GPS independent of scoring systems
Crumley <i>et al.</i> <sup>(42)</sup>	Gastro-oesophageal	65	GPS superior to ECOG*
Leitch <i>et al.</i> <sup>(45)</sup>	Colo-rectal	84	GPS superior to WCC and lymphocytes

WCC, leucocyte count.

\*Eastern Cooperative Oncology Group performance status, which assesses the well-being of patients with cancer and their ability to perform ordinary tasks<sup>(37)</sup>.

**Table 3.** Systemic inflammatory response, as evidenced by C-reactive protein (CRP), as a prognostic factor in primary operable cancer

Study	Tumour type	<i>n</i>	Comments
McMillan <i>et al.</i> <sup>(55)</sup>	Colo-rectal	36	Post-op CRP stage independent
Nozoe <i>et al.</i> <sup>(56)</sup>	Colo-rectal	120	Pre-op CRP stage independent
Nielsen <i>et al.</i> <sup>(57)</sup>	Colo-rectal	456	Pre-op CRP stage independent
Wigmore <i>et al.</i> <sup>(63)</sup>	Colo-rectal	202	Pre- and post-op CRP not stage independent
McMillan <i>et al.</i> <sup>(58)</sup>	Colo-rectal	174	Pre- and post-op CRP stage independent
Chung <i>et al.</i> <sup>(64)</sup>	Colo-rectal	172	Pre-op CRP not stage independent
Nikiteas <i>et al.</i> <sup>(59)</sup>	Colo-rectal	74	Pre-op CRP stage independent
Crozier <i>et al.</i> <sup>(60)</sup>	Colo-rectal	222	Pre-op CRP stage and treatment independent
Wong <i>et al.</i> <sup>(61)</sup>	Colo-rectal, liver	170	Pre-op CRP stage independent
McMillan <i>et al.</i> <sup>(62)</sup>	Colo-rectal	316	GPS independent of stage and treatment

Pre-op, pre-operative; post-op, post-operative; GPS, Glasgow prognostic score.

patient group, with increasing GPS a median reduction was found in Karnofsky performance status<sup>(47)</sup> (25%), Hb (22%), Na(3%), Zn (15%) and survival (93%) and a median increase in leucocyte count (129%), alkaline phosphatase (217%),  $\gamma$ -glutamyl transferase (371%) and lactate dehydrogenase (130%). C-reactive protein concentrations were found to be strongly and similarly correlated with alkaline phosphatase and  $\gamma$ -glutamyl transferase, accounting for >25% of the variation in their activities. Thus, it would appear that chronic activation of the systemic inflammatory response in cancer is associated with important aspects of the general biochemical disturbance in patients with advanced cancer<sup>(46)</sup>.

Thus, it is concluded that the combination of an elevated C-reactive protein concentration and hypoalbuminaemia (the GPS) is a tumour stage and performance status independent prognostic factor in patients with advanced inoperable cancer.

#### Application of a systemic-inflammation-based score in patients with primary cancer

There has also been some work in primary operable cancer that has shown that the systemic inflammatory response, as evidenced by an elevated C-reactive protein concentration, has prognostic value in gastro-oesophageal<sup>(48, 49)</sup>, urinary bladder<sup>(50)</sup>, pancreatic<sup>(51)</sup>, renal<sup>(52,53)</sup> and non-small-cell lung<sup>(54)</sup> cancers, independent of tumour stage (Table 3). Also, a number of studies carried out in primary operable colo-rectal cancer have highlighted the independent prognostic value of an elevated C-reactive

protein concentration<sup>(55–62)</sup>, with only two studies failing to observe such a relationship<sup>(63,64)</sup>.

Recently, the prognostic value of the GPS has been examined in patients with either primary operable colo-rectal cancer (*n* 149) or synchronous unresectable liver metastases (*n* 84)<sup>(65)</sup>. The GPS was found to be a superior predictor of cancer-specific survival compared with leucocyte components of the systemic inflammatory response.

Thus, it is concluded that markers of the systemic inflammatory response, in particular C-reactive protein, are independently associated with survival in patients with primary operable cancer. The combination of an elevated C-reactive protein concentration and hypoalbuminaemia (the GPS) is a tumour stage- and treatment-independent prognostic factor in patients with primary operable colo-rectal cancer.

In summary, it is believed that a measure of the systemic inflammatory response, such as the GPS, should be included together with tumour stage as part of the assessment of the patient with cancer. As a consequence, this approach will highlight the need not only to treat the tumour but also the systemic inflammatory response.

#### Acknowledgements

The author declares no conflict of interest. The author gratefully acknowledges the support and advice of clinical and scientific colleagues at Glasgow Royal Infirmary and funding from Glasgow Royal Infirmary Endowment Funds, the Chief Scientist Office and Cancer Research UK.

## References

1. Cancer Research UK (2006) Statistics on the risk of developing cancer. <http://info.cancerresearchuk.org/cancerstats/incidence/risk/?a=5441>
2. Christakis NA & Lamont EB (2000) Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. *Br Med J* **320**, 469–472.
3. Steensma DP & Loprinzi CL (2000) The art and science of prognosis in patients with advanced cancer. *Eur J Cancer* **36**, 2025–2027.
4. DeWys WD, Begg C, Lavin PT *et al.* (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. *Am J Med* **69**, 491–497.
5. Daly JM, Dudrick SJ & Copeland EM 3rd (1979) Evaluation of nutritional indices as prognostic indicators in the cancer patient. *Cancer* **43**, 925–931.
6. Andreyev HJN, Norman AR, Oates J & Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? *Eur J Cancer* **34**, 503–509.
7. O'Gorman P, McMillan DC & McArdle CS (1998) Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. *Nutr Cancer* **32**, 76–80.
8. O'Gorman P, McMillan DC & McArdle CS (1999) Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. *Nutr Cancer* **35**, 127–129.
9. O'Gorman P, McMillan DC & McArdle CS (2000) Prognostic factors in advanced gastrointestinal cancer patients with weight loss. *Nutr Cancer* **37**, 36–40.
10. Moley JF, Aamodt R, Rumble W, Kaye W & Norton JA (1987) Body cell mass in cancer-bearing and anorexic patients. *J Parenter Enteral Nutr* **11**, 219–222.
11. Fearon KC & Preston T (1990) Body composition in cancer cachexia. *Infusionstherapie* **17**, Suppl. 3, 63–66.
12. McMillan DC, Preston T, Watson WS, Simpson JM, Fearon KC, Shenkin A, Burns HJ & McArdle CS (1994) Relationship between weight loss, reduction of body cell mass and inflammatory response in patients with cancer. *Br J Surg* **81**, 1011–1014.
13. Nelson KA, Walsh D & Sheehan FA (1994) The cancer anorexia-cachexia syndrome. *J Clin Oncol* **12**, 213–225.
14. Toomey D, Redmond HP & Bouchier-Hayes D (1995) Mechanisms mediating cancer cachexia. *Cancer* **76**, 2418–2426.
15. Morley JE, Thomas DR & Wilson MM (2006) Cachexia: pathophysiology and clinical relevance. *Am J Clin Nutr* **83**, 735–743.
16. Fearon KC, Voss AC & Hustead DS for the Cancer Cachexia Study Group (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. *Am J Clin Nutr* **83**, 1345–1350.
17. Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y & Sakai S (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. *Br J Cancer* **85**, 1634–1639.
18. Bozzetti F (1979) Determination of the caloric requirement of patients with cancer. *Surg Gynecol Obstet* **149**, 667–670.
19. Macfie J, Burkinshaw L, Oxby C, Holmfield JHM & Hill GL (1982) The effect of gastrointestinal malignancy on resting metabolic expenditure. *Br J Surg* **69**, 443–446.
20. Hansell DT, Davies JW & Burns HJ (1986) The relationship between resting energy expenditure and weight loss in benign and malignant disease. *Ann Surg* **203**, 240–245.
21. Falconer JS, Fearon KC, Plester CE, Ross JA & Carter DC (1994) Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. *Ann Surg* **219**, 325–331.
22. Staal-van den Brekel AJ, Dentener MA, Schols AM, Buurman WA & Wouters EF (1995) Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. *J Clin Oncol* **13**, 2600–2605.
23. Scott HR, McMillan DC, Watson WS, Milroy R & McArdle CS (2001) Longitudinal study of resting energy expenditure, body cell mass and the inflammatory response in male patients with non-small cell lung cancer. *Lung Cancer* **32**, 307–312.
24. McMillan DC, Scott HR, Watson WS, Preston T, Milroy R & McArdle CS (1998) Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. *Nutr Cancer* **31**, 101–105.
25. Lundholm K, Gelin J, Hylander A *et al.* (1994) Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. *Cancer Res* **54**, 5602–5606.
26. McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE & McArdle CS (1999) A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. *Br J Cancer* **79**, 495–500.
27. Lundholm K, Daneryd P, Körner U, Hylander A & Bosaeus I (2004) Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. *Int J Oncol* **24**, 505–512.
28. Gabay C & Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med* **340**, 448–454.
29. Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. *Science*; **267**, 1456–1462.
30. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J & McArdle CS (2001) Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. *Nutr Cancer* **41**, 64–69.
31. Vermeire S, Van Assche G & Rutgeerts P (2005) The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. *Nat Clin Pract Gastroenterol Hepatol* **2**, 580–586.
32. Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ & Carter DC (1995) Acute-phase protein response and survival duration of patients with pancreatic cancer. *Cancer* **75**, 2077–2082.
33. McMillan DC, Watson WS, Preston T & McArdle CS (2000) Lean body mass changes in cancer patients with weight loss. *Clin Nutr* **19**, 403–406.
34. Mahmoud FA & Rivera NI (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. *Curr Oncol Rep* **4**, 250–255.
35. Maltoni M, Caraceni A, Brunelli C *et al.* (2005) Steering Committee of the European Association for Palliative Care. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations – a study by the Steering Committee of the European Association for Palliative Care. *J Clin Oncol* **23**, 6240–6248.
36. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS & Milroy R (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with

- inoperable non-small cell lung cancer. *Br J Cancer* **87**, 264–267.
37. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET & Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* **5**, 649–655.
  38. Forrest LM, McMillan DC, McArdle CS, Angerson WJ & Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. *Br J Cancer* **89**, 1028–1030.
  39. Forrest LM, McMillan DC, McArdle CS, Angerson WJ & Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. *Br J Cancer* **90**, 1704–1706.
  40. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C & McMillan DC (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. *Br J Cancer* **94**, 227–230.
  41. Crumley AB, McMillan DC, McKernan M, McDonald AC & Stuart RC (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. *Br J Cancer* **94**, 637–641.
  42. Crumley AB, Stuart RC, McKernan M, McDonald AC & McMillan DC (2007) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastro-oesophageal cancer. *J Gastroenterol Hepatol* (Epublication ahead of print version).
  43. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW & McKay CJ (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. *Pancreatol* **6**, 450–453.
  44. Ramsey S, Lamb GW, Aitchison M, Graham J & McMillan DC (2007) Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. *Cancer* **109**, 205–212.
  45. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG & McMillan DC (2007) Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. *Br J Cancer* **97**, 1266–1270.
  46. Brown DJ, Milroy R, Preston T & McMillan DC (2007) The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. *J Clin Pathol* **60**, 705–708.
  47. Karnofsky DA & Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer, In *Evaluation of Chemotherapeutic Agents*, pp. 191–205 [CM MacLeod editor]. New York: Columbia University Press.
  48. Ikeda M, Natsugoe S, Ueno S, Baba M & Aikou T (2003) Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. *Ann Surg* **238**, 197–202.
  49. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ & Stuart RC (2006) An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. *Br J Cancer* **94**, 1568–1571.
  50. Hilmy M, Bartlett JM, Underwood MA & McMillan DC (2005) The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. *Br J Cancer* **92**, 625–627.
  51. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R & Imrie CW (2005) Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. *Br J Cancer* **92**, 21–23.
  52. Lamb GW, McMillan DC, Ramsey S & Aitchison M (2006) The relationship between the preoperative systemic inflammatory response and cancer specific survival in patients undergoing potentially curative resection for renal clear cell cancer. *Br J Cancer* **94**, 781–784.
  53. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J & Patard JJ (2007) C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. *Cancer* **110**, 1241–1247.
  54. Hara M, Matsuzaki Y, Shimizu T, Tomita M, Ayabe T, Enomoto Y & Onitsuka T (2007) Preoperative serum C-reactive protein level in non-small cell lung cancer. *Anticancer Res* **27**, 3001–3004.
  55. McMillan DC, Wotherspoon HA, Fearon KCH, Sturgeon CM, Cooke TG & McArdle CS (1995) A prospective study of tumour recurrence and the acute phase response after apparently curative colorectal cancer. *Am J Surg* **170**, 319–322.
  56. Nozoe T, Matsumata T, Kitamura M & Sugimachi K (1998) Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. *Am J Surg* **176**, 335–338.
  57. Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F & Brunner N (2000) Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. *Ann Surg Oncol* **7**, 617–623.
  58. McMillan DC, Canna K & McArdle CS (2003) Systemic inflammatory response predicts survival following curative resection of colorectal cancer. *Br J Surg* **90**, 215–219.
  59. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, Kostakis A & Peros G (2005) Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. *World J Gastroenterol* **11**, 1639–1643.
  60. Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG & McMillan DC (2006) The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. *Br J Cancer* **94**, 1833–1836.
  61. Wong VK, Malik HZ, Hamady ZZ, Al-Mukhtar A, Gomez D, Prasad KR, Toogood GJ & Lodge JP (2007) C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. *Br J Cancer* **96**, 222–225.
  62. McMillan DC, Crozier JE, Canna K, Angerson WJ & McArdle CS (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. *Int J Colorectal Dis* **22**, 881–886.
  63. Wigmore SJ, McMahon AJ, Sturgeon CM & Fearon KC (2001) Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. *Br J Surg* **88**, 255–260.
  64. Chung YC & Chang YF (2003) Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. *Eur J Gastroenterol Hepatol* **15**, 369–373.
  65. Leitch EF, Chakrabarti M, Crozier JEM, McKee RF, Anderson JH, Horgan PG & McMillan DC (2007) Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. *Br J Cancer* **97**, 1266–1270.